

2. Burzynski SR. Antineoplastons – history of the research (I). *Drug Exp Clin Res* 1986; 12: 1-9
3. Burzynski SR. Biologically active peptides in human urine: I. Isolation of a group of medium-sized peptides. *Physiol Chem Phys* 1973; 5: 437-47
4. Burzynski SR, Loo TL, Ho DH, et al. Biologically active peptides in human urine: III. Inhibitors of the growth of leukemia, osteosarcoma and HeLa cells. *Physiol Chem Phys* 1976; 8: 13-22
5. Gross S, Galicka N, Grabarczyk M, et al. Urinary peptides inhibit DNA synthesis in vitro in certain cultured neoplastic cells. *Clin Chem* 1977; 23: 148-9
6. Beall P, Szopa B, Burzynski SR, et al. Polypeptides that inhibit human breast cancer division. *Cancer Biochem Biophys* 1979; 3: 93-6
7. Burzynski SR. Antineoplastons: biochemical defense against cancer. *Physiol Chem Phys* 1976; 8: 275-9
8. Burzynski SR. Isolation, purification and synthesis of antineoplastons. *Int J Exp Clin Chemother* 1989; 2: 63-9
9. Burzynski SR. Novel differentiation inducers. In: Adam D, editor. *Recent Advances in Chemotherapy*. Munich: Futuramed Publishers, 1992
10. Burzynski SR. Synthetic antineoplastons and analogs. *Drugs Future* 1986; 11: 679-88
11. Burzynski SR. Immunosurveillance versus chemosurveillance. *Postepy Nauk Medycznych* 1993; 6: 260-2
12. Burzynski SR, Kubove E, Burzynski B. Treatment of hormonally refractory cancer of the prostate with antineoplaston AS2-1. *Drugs Exp Clin Res* 1990; 16: 361-9
13. Burzynski SR, Hendry LB, Mohabbat MO, et al. Purification, structure determination, synthesis and animal toxicity studies of antineoplaston A10. *Proceedings of the Thirteenth International Congress on Chemotherapy: 1983 Aug 28-Sep 2; Vienna*
14. Ashraf AQ, Liau MC, Mohabbat MO, et al. Preclinical studies of antineoplaston A10 injections. *Drugs Exp Clin Res* 1986; 12 Suppl. 1: 37-45
15. Burzynski SR, Mohabbat MO, Lee SS. Preclinical studies of antineoplaston AS2-1 and antineoplaston AS2-5. *Drugs Exp Clin Res* 1986; 12 Suppl. 1: 11-6
16. Zetterberg A, Engstrom W. Glutamine and the regulation of DNA replication and cell multiplication in fibroblasts. *J Cell Physiol* 1981; 108: 365-73
17. Szkudlinski M, Lewinski A, Rybicka I, et al. Glutamine derivatives as novel anticancer agents acting via gastrin binding sites. *Med Hypotheses* 1990; 32: 85-8
18. Turowski GA, Rashid Z, Hong F, et al. Glutamine modulates phenotype and stimulates proliferation in human colon cancer cell lines. *Cancer Res* 1994; 54: 5974-80
19. Burzynski SR. Phase I clinical studies of antineoplaston AS2-5 injections. In: Ishigami J, editor. *Recent advances in chemotherapy*. Tokyo: University of Tokyo Press, 1985
20. Lehner AF, Burzynski SR, Hendry LB. 3-phenylacetylaminio-2,6-piperidinedione, a naturally occurring peptide analog with apparent antineoplastic activity may bind to DNA. *Drugs Exp Clin Res* 1986; 12 Suppl. 1: 57-72
21. Hendry LB, Muldoon TG, Burzynski SR, et al. Stereochemical modeling studies of the interaction of antineoplaston A10 with DNA. *Drugs Exp Clin Res* 1987; 13 Suppl. 1: 77-81
22. Hendry LB, Muldoon TG, Burzynski SR. Modeling studies suggest the modified dipeptide analog phenylacetylaminio-2,6-piperidinedione may interact with DNA. *Adv Exp Clin Chemother* 1988; 2: 11-3
23. Michalska D. Theoretical investigations on the structure and potential binding sites of antineoplaston A10 and experimental findings. *Drugs Exp Clin Res* 1990; 16: 342-9
24. Michalska D. MNDO studies on the structure of antineoplaston A10, glutarimide and piperidine. *J Mol Structure* 1991; 231: 357-66
25. Hendry LB, Chu CK, Huang JC, et al. Structure-activity relationships, molecular modeling and antitumor activity of phenylacetylaminio-2,6-piperidinediones. In: Adam D, editor. *Recent advances in chemotherapy*. Munich: Futuramed Publishers, 1991
26. Liau MC, Burzynski SR. Altered methylation complex isoenzymes as selective targets for cancer chemotherapy. *Drugs Exp Clin Res* 1986; 12 Suppl. 1: 77-86
27. Liau MC, Lee SS, Burzynski SR. Modulation of cancer methylation complex isozymes as a decisive factor in the induction of terminal differentiation mediated by antineoplaston A5. *Int J Tissue React* 1990; 12 Suppl.: 27-36
28. Liau MC, Liau CP, Burzynski SR. Potentiation of induced terminal differentiation by phenylacetic acid and related chemicals. *Int J Exp Clin Chemother* 1992; 5: 9-17
29. Holliday R. The inheritance of epigenetic defects. *Science* 1987; 238: 163-70
30. Charache S, Dover G, Smith K, et al. Treatment of sickle cell anemia with 5-azacytidine results in increased fetal hemoglobin production and is associated with nonrandom hypomethylation of DNA around the  $\beta$ - $\gamma$ - $\delta$ -globin gene complex. *Proc Natl Acad Sci USA* 1983; 80: 4842-6
31. Reik W. Genomic imprinting and genetic disorders in man. *Trends Genet* 1989; 5: 331-6
32. Ferguson-Smith AC, Reik W, Surani MA. Genomic imprinting and cancer. *Cancer Surv* 1990; 9: 487-503
33. Lee WH, Morton RA, Epstein JI, et al. Cytidine methylation of regulatory sequences near the  $\pi$ -class glutathione S-transferase gene accompanies human prostatic carcinogenesis. *Proc Natl Acad Sci USA* 1994; 91: 11733-7
34. Liau MC, Lee SS, Burzynski SR. Hypomethylation of nucleic acids: a key to the induction of terminal differentiation. *Int J Exp Clin Chemother* 1989; 2: 187-99
35. Liau MC, Luong Y, Liau CP, et al. Prevention of drug-induced DNA hypermethylation by antineoplastons. In: Adam D, editor. *Recent advances in chemotherapy*. Munich: Futuramed Publishers, 1992
36. Dover G, Brusilow S, Samid D. Increased fetal hemoglobin in patients receiving sodium 4-phenylbutyrate. *N Eng J Med* 1992; 327: 569-70
37. Burzynski SR, Kubove E. Phase I clinical studies of antineoplaston A3 injections. *Drugs Exp Clin Res* 1987; 13 Suppl. 1: 17-29
38. Burzynski SR, Kubove E, Burzynski B. Phase I clinical studies of oral formulation of antineoplaston A3. *Tenth International Congress on Pharmacology: 1987 Aug 23-28; Sydney*
39. Burzynski SR. Methods for treating neurofibromatosis. US Patent No. 5391575
40. Buday L, Downward J. Epidermal growth factor regulates p21ras through the formation of a complex receptor, Grb2 adapter protein, and Sos nucleotide exchange factor. *Cell* 1993; 73: 611-20
41. Lupu R, Colomer R, Zugmaier G, et al. Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185erbB2. *Science* 1990; 249: 1552-5
42. Wen D, Peles E, Cupples R, et al. Neu differentiation factor: a transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit. *Cell* 1992; 69: 559-72